Overview

A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Status:
Completed

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare several Debio 025 (alisporivir)/peg-IFNα2a/ribavirin triple therapies with the current standard of care (SOC) in treatment naïve chronic hepatitis C genotype 1 patients.

Phase:

N/A

Details

Lead Sponsor:

Debiopharm International SA

Collaborator:

Parexel

Treatments:

Cyclosporine
Interferon-alpha
Peginterferon alfa-2a
Ribavirin